AI Article Synopsis
- Hymenoptera venom allergy significantly affects quality of life, and while allergen immunotherapy (AIT) is effective, predicting its success remains challenging due to a lack of biomarkers.
- This study analyzed patient data from 1985 to 2022 at the University Hospital of Limoges to assess the role of IgE blocking activity as a potential predictor of AIT efficacy against Hymenoptera venom.
- Results indicated that IgE blocking activity did not predict relapse after stopping AIT, but a correlation was found between this activity and IgG antibody levels, suggesting that further research is needed to explore the role of these antibodies in monitoring treatment outcomes.
Article Abstract
Background: Hymenoptera venom allergy is a public health issue and has an undeniable impact on quality of life. Allergen immunotherapy (AIT) has shown long-term efficacy in this severe and potentially lethal allergy. However, no biomarker can predict the effectiveness of this treatment.
Objectives: We evaluated the contribution of IgE blocking activity, a functional biomarker carried out in our center using flow cytometry, to predict the efficacy of AIT.
Methods: This retrospective study from 1985 to 2022 describes in detail the demographic, clinical, and biological characteristics of patients who benefited from AIT with Hymenoptera venom at the University Hospital of Limoges. The outcome measure used was the presence of anaphylactic reaction (grade I to IV according to Ring and Messmer) in case of a new sting after discontinuation of AIT.
Results: Our study, mainly composed of patients allergic to wasp venom, did not emphasize the interest of IgE blocking activity in the prediction of a relapse after a new sting. However, this inhibition showed a significant correlation with the amount of IgG antibodies.
Conclusion: There is no biomarker that can help make the decision of stopping AIT. However, low levels of IgE blocking activity may suggest a likelihood of relapse. Serum IgG, in correlation with IgE blocking activity, could be useful for monitoring treatment response. Additional studies are necessary to gain a thorough understanding of the composition of inhibitory antibodies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415340 | PMC |
| http://dx.doi.org/10.1016/j.jacig.2024.100329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.
Allergy
December 2024
Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
Background: Peanut allergy is a potentially life-threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)-4/IL-13, improved safety and desensitization to peanut exposure in children with peanut allergy.
Methods: A Phase II, 24-week, multicenter, single-arm, open-label, proof-of-concept study was conducted in the USA and Canada (NCT03793608).
Occupational anaphylaxis: A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI).
Allergol Select
November 2024
Department of Dermatology and Allergy Biederstein, School of Medicine and Health, Technical University of Munich TUM).
Background: Anaphylaxis is a systemic allergic reaction that is potentially life-threatening. Occupational anaphylaxis is an anaphylaxis that occurs in an occupational context. In this position paper, we propose diagnostic criteria for occupational anaphylaxis and provide an overview of the current state of knowledge in terms of prevalence, triggers, prevention, and management.
View Article and Find Full Text PDFMilk protein sensitivity is a major challenge in infant feeding, especially for infants who cannot receive adequate breastfeeding. Hydrolyzed milk protein is a mainstream way to address this difficulty. The aim of this study was to assess the effect of differences in whey protein concentrate (WPC) source and the degree of hydrolysis on blocking allergy and to analyze the possible mechanisms by which hydrolyzed infant formula (IF) blocks allergy through colony-metabolism-immunity response.
View Article and Find Full Text PDFActivation of mouse skin mast cells and cutaneous afferent C-fiber subtypes by bee venom.
Neurosci Lett
January 2025
Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Cir, Baltimore, MD 21224, USA. Electronic address:
In mammals, many Hymenopteran stings are characterized by pain, redness, and swelling - three manifestations consistent with nociceptive nerve fiber activation. The effect of a Western honeybee (Apis mellifera) venom on the activation of sensory C-fibers in mouse skin was studied using an innervated isolated mouse skin preparation that allows for intra-arterial delivery of chemicals to the nerve terminals in the skin. Our data show that honeybee venom stimulated mouse cutaneous nociceptive-like C-fibers, with an intensity (action potential discharge frequency) similar to that seen with a maximally-effective concentration of capsaicin.
View Article and Find Full Text PDFTherapies for Chronic Spontaneous Urticaria: Present and Future Developments.
Pharmaceuticals (Basel)
November 2024
Department of Pathophysiology and Transplantation, Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, 20122 Milan, Italy.
Chronic spontaneous urticaria (CSU) is a complex dermatological condition characterized by recurrent wheals and/or angioedema lasting for more than six weeks, significantly impairing patients' quality of life. According to European guidelines, the first step in treatment involves second-generation H1-antihistamines (sgAHs), which block peripheral H1 receptors to alleviate symptoms. In cases with inadequate responses, the dose of antihistamines can be increased by up to fourfold.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!